publication date: Jun. 2, 2016

Precision Medicine

Study: Precision Medicine Yields Better Outcomes in Phase I Clinical Trials

 

A meta-analysis of 346 phase I clinical trials, involving more than 13,000 patients, found that selecting treatment based on a tumor’s molecular characteristics led to significantly better outcomes.

“Our study suggests that, with a precision medicine approach, we can use a patient’s individual tumor biomarkers to determine whether they are likely to benefit from a particular therapy, even when that therapy is at the earliest stage of clinical development,” said lead study author Maria Schwaederle, of the Center for Personalized Cancer Therapy at the University of California, San Diego. “This strategy often results in good outcomes for patients, and I hope it will encourage and reassure doctors and patients considering enrollment in precision medicine-based phase I trials.”

According to the authors, this is the first study to show that such benefits are apparent even at the first stage of clinical development. It suggests that tumor biomarkers should be increasingly used to select patients for phase I clinical trials. The study will be presented at the annual meeting of the American Society of Clinical Oncology.

Continue reading CCL May – Precision Medicine Study: Precision Medicine Yields Better Outcomes in Phase I Clinical Trials

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.